
    
      The study is a prospective, randomised, parallel group, double-blind, placebo-controlled,
      Phase 3 study to confirm the efficacy and the safety of nolasiban versus placebo to increase
      pregnancy and live birth rates in 820 women undergoing fresh single blastocyst transfer
      following in vitro fertilisation (IVF) or intra-cytoplasmic sperm injection (ICSI).
    
  